Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Ratio (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 7 years of Equity Ratio readings, the most recent being 0.73 for Q1 2026.

  • On a quarterly basis, Equity Ratio fell 3.85% to 0.73 in Q1 2026 year-over-year; TTM through Mar 2026 was 0.73, a 3.85% decrease, with the full-year FY2025 number at 0.74, down 1.58% from a year prior.
  • Equity Ratio hit 0.73 in Q1 2026 for Kiniksa Pharmaceuticals International, down from 0.74 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2023 to a low of 0.72 in Q1 2022.
  • Median Equity Ratio over the past 5 years was 0.79 (2024), compared with a mean of 0.79.
  • Biggest five-year swings in Equity Ratio: decreased 17.26% in 2022 and later rose 22.38% in 2023.
  • Kiniksa Pharmaceuticals International's Equity Ratio stood at 0.86 in 2022, then fell by 3.25% to 0.83 in 2023, then decreased by 9.42% to 0.76 in 2024, then fell by 1.58% to 0.74 in 2025, then dropped by 1.26% to 0.73 in 2026.
  • The last three reported values for Equity Ratio were 0.73 (Q1 2026), 0.74 (Q4 2025), and 0.75 (Q3 2025) per Business Quant data.